TY - JOUR
T1 - To Prescribe or Not to Prescribe?
T2 - Barriers and Motivators for Progressing Along Each Stage of the Buprenorphine Training and Prescribing Path
AU - Winograd, Rachel P.
AU - Coffey, Bridget
AU - Woolfolk, Candice
AU - Wood, Claire A.
AU - Ilavarasan, Vinith
AU - Liss, David
AU - Jain, Subodh
AU - Stringfellow, Erin
N1 - Funding Information:
Funding for this research was provided by the Substance Abuse and Mental Health Services Administration (Grant number 1H79TI081697).
Publisher Copyright:
© 2021, National Council for Mental Wellbeing.
PY - 2023/4
Y1 - 2023/4
N2 - This study aimed to identify the strongest barriers and motivators associated with each step toward buprenorphine prescribing (1. obtaining a waiver, 2. beginning to prescribe, and 3. prescribing to more people) among a sample of Missouri-based medical professionals (N = 130). Item weights (number of endorsements times mean rank of the item’s importance) were calculated based on their responses. Across groups, lack of access to psychosocial support services, need for higher levels of care, and clinical complexity were strong barriers. Among non-prescribers (n = 57, 46.3%), administrative burden, potential of becoming an addiction clinic, and concern about misuse and diversion were most heavily weighted. Among prescribers (n = 66, 53.7%), patients’ inability to afford medications was a barrier across phases. Prominent motivators among all groups were the effectiveness of buprenorphine, improvement in other health outcomes, and a personal interest in treating addiction. Only prescribers reported the presence of institutional support and mentors as significant motivators.
AB - This study aimed to identify the strongest barriers and motivators associated with each step toward buprenorphine prescribing (1. obtaining a waiver, 2. beginning to prescribe, and 3. prescribing to more people) among a sample of Missouri-based medical professionals (N = 130). Item weights (number of endorsements times mean rank of the item’s importance) were calculated based on their responses. Across groups, lack of access to psychosocial support services, need for higher levels of care, and clinical complexity were strong barriers. Among non-prescribers (n = 57, 46.3%), administrative burden, potential of becoming an addiction clinic, and concern about misuse and diversion were most heavily weighted. Among prescribers (n = 66, 53.7%), patients’ inability to afford medications was a barrier across phases. Prominent motivators among all groups were the effectiveness of buprenorphine, improvement in other health outcomes, and a personal interest in treating addiction. Only prescribers reported the presence of institutional support and mentors as significant motivators.
KW - Barriers
KW - Buprenorphine
KW - Motivators
KW - Opioid use disorder
KW - Treatment
KW - Waiver
UR - http://www.scopus.com/inward/record.url?scp=85123256688&partnerID=8YFLogxK
U2 - 10.1007/s11414-021-09783-z
DO - 10.1007/s11414-021-09783-z
M3 - Article
C2 - 35060002
AN - SCOPUS:85123256688
SN - 1094-3412
VL - 50
SP - 165
EP - 180
JO - Journal of Behavioral Health Services and Research
JF - Journal of Behavioral Health Services and Research
IS - 2
ER -